Skip to content

Welcome to Discover Pharma! Today is : October 21, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

iPSC

  • Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas

    Researchers develop human iPS cell model of heart failure

    Researchers have developed a human iPS-cell-derived heart tissue model of [...]

    September 16, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    PRISM ALS initiative develops patient-derived stem cell models to improve ALS/MND drug discovery

    A new global initiative aims to address long-standing limitations in [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Digital & Data,Opinion & Events

    Cellino and Karis Bio join forces to deliver personalized cell therapy in Asia-Pacific

    Cellino and Karis Bio have announced a strategic partnership to [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business

    Cellevate consortium secures €1M Eurostars grant to boost iPSC manufacturing at scale

    May 5, 2026
  • Advanced Therapies

    Cellistic unveils Echo-NK platform to scale up iPSC-based cell therapies

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Olink assay correlates with ELISA for measuring endothelin-1
    Categories: Clinical & Regulatory, Research & Development
  • BridgeBio gets FDA Priority Review for oral infigratinib in achondroplasia
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • ViiV’s Cabenuva achieves superior viral suppression in CROWN Phase 3b study
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top